[1] 夏小雯, 孙亚, 宋春红, 等. 芍药苷抗抑郁的相关研究进展[J].世界科学技术: 中医药现代化, 2019, 21(5):912-917. [2] Song CH, Wang JQ, Gao DM, et al.Paeoniflorin, the main active ingredient of shuyu capsule, inhibits Cav1.2 and regulates calmodulin/calmodulin-dependent protein kinase Ⅱ signalling[J]. Bio Med Res Int, 2017: 8459287. [3] Kim HC, Ko KH, Kim WK, et al.Effects of dextromethorphan on the seizures induced by kainate and the calcium channel agonist BAY k-8644: Comparison with the effects of dextrorphan[J]. Behav Brain Res, 2001, 120(2):169. [4] 林易玮, 张雨晨, 王澜凝, 等. 抗抑郁抗焦虑药物的药理与临床[J]. 实用药物与临床, 2020, 23(1):1-4. [5] 苏文君, 王继军. CACNA1C基因在精神障碍中的遗传影像学研究进展[J]. 中国神经精神疾病杂志, 2019, 45(9):573-576. [6] 李艺杰, 王美艳, 薛玲, 等. 舒郁胶囊对PMDD肝气郁证模型大鼠Cav1.2介导的CaM/CaMKⅡ信号通路的影响[J].中国实验方剂学杂志, 2018, 24(10):130-136. [7] 徐凯勇, 王杰琼, 李芳, 等. 舒郁胶囊及其主要组份对经前期综合征肝气郁证大鼠海马中Cav1.2介导的CaM/CaMKⅡ信号通路的影响[J]. 实验动物与比较医学,2019, 39(5):377-382. [8] Leggio GM, Salomone S, Bucolo C, et al.Dopamine D(3) receptor as a new pharmacological target for the treatment of depression[J]. Eur J Pharmacol, 2013, 719(3):25-33. [9] Dwivedi Y, Rizavi HS, Zhang H, et al.Neurotrophin receptor activation and expression in human postmortem brain: effect of suicide[J]. Biol Psychiatry, 2009, 65(4):319-328. [10] Polyakova M, Stuke K, Schuemberg K, et al.BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis[J]. J Affect Disord, 2015, 174:432-440. [11] 刘迪, 唐倩倩, 曹君利, 等. 脑源性生长因子参与疼痛-抑郁共病的研究进展[J]. 中国药理学通报, 2015, 31(1):26-30. [12] Lepack AE, Fuchikami M, Dwyer JM, et al. BDNF release is required for the behavioral actions of ketamine[J]. Int J Neuropsychopharmacol, 2015, 18(1):pyu033. [13] 宋春红, 王杰琼, 李芳, 等. 白芍提取物对PMS肝气郁证大鼠下丘脑Cav1.2介导的CaM/CaMK Ⅱ/BDNF信号通路的影响[J]. 世界科学技术: 中医药现代化, 2016, 18(10):1794-1800. [14] 王海涛, 刘昊, 徐爱军, 等. 慢性强迫游泳应激抑郁模型大鼠行为学及海马Ca2+/钙调蛋白依赖性激酶Ⅱ的变化[J]. 解剖学报, 2009, 40(6):881-885. |